Menu
Search
|

Menu

Close
X

Spectrum Pharmaceuticals Inc SPPI.OQ (NASDAQ Stock Exchange Global Select Market)

22.49 USD
+2.03 (+9.92%)
As of Feb 23
chart
Previous Close 20.46
Open 20.83
Volume 514,264
3m Avg Volume 454,426
Today’s High 22.64
Today’s Low 20.82
52 Week High 23.50
52 Week Low 5.47
Shares Outstanding (mil) 100.66
Market Capitalization (mil) 2,263.89
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
100
FY16
146
FY15
163
EPS (USD)
FY17
-0.777
FY16
-0.935
FY15
-0.780
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.62
Price to Sales (TTM)
vs sector
16.77
8.35
Price to Book (MRQ)
vs sector
6.94
5.22
Price to Cash Flow (TTM)
vs sector
--
25.88
Total Debt to Equity (MRQ)
vs sector
33.40
15.84
LT Debt to Equity (MRQ)
vs sector
33.40
12.39
Return on Investment (TTM)
vs sector
-19.21
13.63
Return on Equity (TTM)
vs sector
-28.65
15.39

EXECUTIVE LEADERSHIP

Stuart Krassner
Chairman of the Board, Since 2017
Salary: --
Bonus: --
Joseph Turgeon
President, Chief Executive Officer, Director, Since 2017
Salary: $593,750.00
Bonus: $345,000.00
Kurt Gustafson
Chief Financial Officer, Executive Vice President, Since 2013
Salary: $492,500.00
Bonus: $235,000.00
Thomas Riga
Chief Operating Officer, Since 2017
Salary: --
Bonus: --
Luigi Lenaz
Lead Independent Director, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

11500 S Eastern Ave Ste 240
HENDERSON   NV   89052-5576

Phone: +1702.8356300

Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has a product portfolio consisting of both commercial stage and development stage products that address various cancer types. The Company has six approved oncology/hematology products that target different types of cancer, including non-Hodgkin's lymphoma (NHL), advanced metastatic colorectal cancer (mCRC), acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has three drugs in mid-to-late stage development, which include ROLONTIS for chemotherapy-induced neutropenia; QAPZOLA for immediate intravesical instillation in post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer (NMIBC), and POZIOTINIB, a pan-human epidermal growth factor receptor (HER) inhibitor used in the treatment of patients with a range of solid tumors, including breast and lung cancer.

SPONSORED STORIES